AMAG Pharmaceuticals, Inc. to Host Conference Call on November 1, 2012 at 8:00 a.m. ET to Discuss Financial Results for the Quarter Ended September 30, 2012
LEXINGTON, Mass.--(BUSINESS WIRE)-- AMAG Pharmaceuticals, Inc. (NAS: AMAG) today announced it will report unaudited consolidated financial results for the quarter ended September 30, 2012 before the U.S. financial markets open on Thursday, November 1, 2012. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET during which management will provide a business update and review third quarter financial results.
To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 12:00 p.m. ET on November 1, 2012 through midnight November 8, 2012. To access a replay of the conference call, dial (855) 859-2056 from the United States or (404) 537-3406 for international access. The pass code for the live call and the replay is 37432497.
The call will be webcast with slides and accessible through the Investors section of the company's website at www.amagpharma.com. The webcast replay will be available from approximately 11:00a.m. ET on November 1, 2012 through midnight November 30, 2012.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. For additional company information, please visit www.amagpharma.com.
Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc.
Amy Sullivan, 617-498-3303
KEYWORDS: United States North America Massachusetts
The article AMAG Pharmaceuticals, Inc. to Host Conference Call on November 1, 2012 at 8:00 a.m. ET to Discuss Financial Results for the Quarter Ended September 30, 2012 originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.